1. Kansas State University
  2. »Division of Communications and Marketing
  3. »K-State Today
  4. »A summary of university changes related to COVID-19

K-State Today

Division of Communications and Marketing
Kansas State University
128 Dole Hall
1525 Mid-Campus Drive North
Manhattan, KS 66506
785-532-2535
vpcm@k-state.edu

May 4, 2020

A summary of university changes related to COVID-19

Submitted by Communications and Marketing

Here's a summary of changes published April 27 to May 2 in response to the COVID-19 pandemic.

K-State auxiliary units announce emergency furloughs

In response to shortfalls in revenue, several auxiliary operations at the university are furloughing workers during the summer season. The units affected include Housing & Dining, Recreational Services, Center for Child Development, Lafene Health Center and K-State Student Union. An estimated 349 employees will be furloughed. Read more in the K-State Today Special Issue from Saturday, May 2.  

Key principles will guide the university's budget as K-State faces challenges head on.

President Richard Myers wrote a letter in a Special Issue of K-State Today on Wednesday, April 29, that outlined the steps that the university will take in response to budget challenges and difficult personal choices.

U.S. CARES Act funding is available for qualified students.

In a letter to faculty and staff on Friday, May 1, Karen Goos shared information about the distribution of the federal Coronavirus Aid, Relief and Economic Security, or CARES, Act funding is available to students. There also is a letter from Robert Gamez in today's student edition

COVID-19 testing for university students and employees is now available.

Kansas State University is helping combat coronavirus by developing important diagnostic tests and offering testing services for the university community.

K-State also expanded licensing agreement for COVID-19 antiviral treatment

Researchers from Kansas State University are doing their part to help discover a treatment for COVID-19 through a second licensing agreement with Cocrystal Pharma.